Document:

CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE
    24B-2	EXHIBIT 10.6

 

Certain confidential portions of this Exhibit, indicated by
[*], have been omitted pursuant to Rule 24b-2 of the Securities Exchange Act of 1934. The omitted materials have been filed separately
with the U.S. Securities and Exchange Commission.

 

 

AMENDED AND RESTATED

 

LICENSE AGREEMENT

 

BETWEEN

 

NAVIDEA BIOPHARMACEUTICALS, INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE NO. SD1998-088

 

     

     

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	RECITALS	 	1
	Article 1	DEFINITIONS	2
	Article 2	GRANTS	5
	Article 3	CONSIDERATION	6
	Article 4	REPORTS, RECORDS AND PAYMENTS	13
	Article 5	PATENT MATTERS	16
	Article 6	GOVERNMENTAL MATTERS	19
	Article 7	TERMINATION OR EXPIRATION OF THE AGREEMENT	20
	Article 8	LIMITED WARRANTY AND INDEMNIFICATION	21
	Article 9	USE OF NAMES AND TRADEMARKS	24
	Article 10	MISCELLANEOUS PROVISIONS	24

 

 

    	 	i	 

     

    

 

AMENDED
AND RESTATED LICENSE AGREEMENT

 

This amended and restated license agreement
directed toward Lymphoseek® (“Agreement”) is made by and between Navidea Biopharmaceuticals, Inc., a Delaware
corporation having an address at 5600 Blazer Parkway, Suite 200, Dublin, OH 43017-1367 (“LICENSEE”) and The
Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin
Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address
at University of California, San Diego, Office of Innovation & Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla,
California 92093-0910 (“UCSD”).

 

The following agreements (“Prior
Agreements”): a License Agreement effective January 26, 2002 (UC Control No. 2002-03-0237), an Amendment No. 1 effective
May 27, 2003 (UC Control No. 2006-03-0237 (REVA)), an Amendment No. 2 effective February 1, 2006 (UC Control No. 2006-03-0237 (REVB)),
an Amendment No. 3 effective August 16, 2011 (UC Control No. 2006-03-0237 (REVC)), and an Amended and Restated License Agreement
effective July 14, 2014, and an Amendment effective May 13, 2016 are hereby amended and restated in their entirety under this Agreement
as of the date of the last signature (“Effective Date”), except that LICENSEE is not relieved of any obligations
or liability that accrued under the Prior Agreements prior to the Effective Date, including LICENSEE'S payment obligations.

 

RECITALS

 

WHEREAS, the invention disclosed
in UCSD Disclosure Docket No. SD 1998-088 and titled “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”
(“Invention”), were made in the course of research at UCSD by Dr. David Vera (hereinafter the “Inventor”)
and are covered by Patent Rights as defined below;

 

WHEREAS, the research was sponsored
in part by the Government of the United States of America and as a consequence this license is subject to overriding obligations
to the Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations;

 

WHEREAS, the Inventor is an employee
of UCSD, and he is obligated to assign all of his right, title and interest in the Invention to UNIVERSITY;

 

WHEREAS, UNIVERSITY provided to LICENSEE
a copy of a representation that the Inventor, to the extent that he is actually aware as of the date of signing of the representation,
has not assigned said rights to a party other than The Regents of the University of California, and has not licensed said rights
to any third party;

 

WHEREAS, UNIVERSITY is desirous that
the Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public;

 

WHEREAS, LICENSEE is desirous of
obtaining certain rights from UNIVERSITY for commercial development, use, and sale of the Invention, and the UNIVERSITY is willing
to grant such rights;

 

    	 	1	 

     

    

 

 

WHEREAS, on or about the Effective
Date, Invention and Patent Rights are to be concurrently licensed to Cardinal Health 414, LLC (the “Cardinal Agreement”),
in accordance with the Asset Purchase Agreement by and between Cardinal Health 414, LLC and LICENSEE (“Cardinal/Navidea Agreement”);

 

WHEREAS, this Agreement is intended
to clarify LICENSEE’S rights and interest in Invention and Patent Rights in light of the Cardinal Agreement, but in no event
will UNIVERSITY be responsible for resolving disagreements or disputes between the obligations and/or performance under the Cardinal
Agreement, the Cardinal/Navidea Agreement and those set forth in this Agreement;

 

WHEREAS, LICENSEE and UNIVERSITY
both desire for their mutual benefit to extend the Term (as defined below) of the Agreement beyond the expiration date of the Patent
Rights (as defined below); and

 

WHEREAS, LICENSEE understands that,
subject to the provisions of Article 10.2, UNIVERSITY may publish or otherwise disseminate information concerning the Invention
and Technology (as defined below) at any time and that LICENSEE is paying consideration thereunder for its early access to the
Invention and Technology, not continued secrecy therein.

 

NOW, THEREFORE, the parties agree:

 

Article
1. DEFINITIONS

 

The terms, as defined herein, shall have
the same meanings in both their singular and plural forms.

 

1.1             
“Affiliate” means any corporation or other business entity which is bound in writing by LICENSEE
to the terms set forth in this Agreement and in which LICENSEE owns or controls, directly or indirectly, at least twenty percent
(20%) of the outstanding stock or other voting rights entitled to elect directors, or in which LICENSEE is owned or controlled
directly or indirectly by at least twenty percent (20%) of the outstanding stock or other voting rights entitled to elect directors;
but in any country where the local law does not permit foreign equity participation of at least twenty percent (20%), then an “Affiliate”
includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage
of outstanding stock or voting rights permitted by local law.

 

1.2             
“CAH Product” means any product used for (1) lymphatic mapping, (2) lymph node biopsy, and (3) the
diagnosis of metastatic spread to lymph nodes for the staging of cancer including but not limited to the radioactive diagnostic
agent product marketed under the Lymphoseek® trademark for current approved indications by the FDA and similar indications
approved by the FDA in the future.

 

1.3             
“Cardinal Health” means Cardinal Health 414, LLC and its permitted successors and assigns under Cardinal
Health's license agreement with the University.

 

1.4             
“Combination Product” means any product which is a Licensed Product (as defined below) and contains
other product(s) or product component(s) that is not an excipient, diluent, adjuvant, buffer, labeling agent(s) such as radioisotope
and fluorescent tag, and the like and (i) does not use Invention, Technology or Patent Rights (as defined below); (ii) the sale,
use or import by itself does not contribute to or induce the infringement of Patent Rights; (iii) is sold separately by LICENSEE,
its Sublicensee (as defined below) or an Affiliate; and (iv) enhances the market price of the final product(s) sold, used or imported
by LICENSEE, its Sublicensee, or an Affiliate.

 

    	 	2	 

     

    

 

1.5             
"Commercially Reasonable Efforts" mean, as the case may be, exerting such efforts and employing such
resources as would normally and objectively be exerted or employed by a similarly situated company for a product of similar market
potential, profit potential and strategic value at a similar stage of its product life, taking into account the competitiveness
of the relevant marketplace, the patent, intellectual property and development positions of third parties, the applicable regulatory
situation, the pricing/reimbursement situation, the commercial viability of the product and other relevant development and commercialization
factors based upon then-prevailing conditions. In no case will Commercially Reasonable Efforts include the LICENSEE ceasing development
and pursuit of approvals for pricing, reimbursement by appropriate agencies, and marketing by Relevant Regulatory Agencies of Licensed
Product for longer than twelve (12) months in countries defined in 3.3a ii (A) and six (6) months in countries defined in 3.3a
ii (B) (excluding any cessation of activity due to safety concerns or otherwise requested or required by a Relevant Regulatory
Agency).

 

1.6             
“Distributor” means a third party that acquires Licensed Product from LICENSEE, Sublicensee, or an
Affiliate and resells directly or indirectly such Licensed Product to End Users.

 

1.7             
“End User” means a person or an entity that acquires a Licensed Product for use in the Field rather
than for development, resale or distribution.

 

1.8             
“Ex-America” means anywhere in the world, except for Canada, Mexico, the United States of America,
and their respective territories and possessions.

 

1.9             
“Ex-America Product” means any CAH Product that is marketed, sold or distributed anywhere in the
Ex-America.

 

1.10         
“Excluded Product” means a CAH Product; (ii) provides for or facilitates any test or procedure that
is reasonably substitutable for any test or procedure provided for or facilitated by the CAH Product; or (iii) is marketed by LICENSEE
for unapproved uses that allow such product to compete with the CAH Product.

 

1.11         
“EPO Member States” means Austria, Belgium, Switzerland, Cyprus, Germany, Denmark, Spain, Finland,
France, Turkey, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Sweden, and the United Kingdom.

 

1.12         
“Field” means diagnostic uses in the targeting of CD206 receptor positive cells residing in the lymph
nodes with a radio-labeled-carbohydrate-conjugated macromolecule.

 

1.13         
“Indication” means a human clinical condition for which use of a Licensed Product requires regulatory
approval by the United States Food and Drug Administration (FDA) or a foreign equivalent. Each Indication under development herein
shall be sequentially identified as a “First Indication”, “Second Indication”, and so on,
with the understanding that each Indication so identified is distinct from every other Indication under development or developed.

 

    	 	3	 

     

    

 

1.14         
“Licensed Method” means any method that uses Technology, or that is claimed in Patent Rights (as
defined below), the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement,
an inducement to infringe or contributory infringement, of any pending or issued claim within Patent Rights.

 

1.15         
“Licensed Product” means any New Product or Ex-America Product that uses Technology, or that is claimed
in Patent Rights, or that is produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation of
which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe
or contributory infringement, of any pending or issued claim within the Patent Rights.

 

1.16         
“Net Sales” means the gross amounts invoiced to third parties for Licensed Products sold or leased
by LICENSEE, Sublicensee, or its Affiliate, or in any combination thereof, less the sum of the following actual and customary deductions
where applicable and separately listed: cash, trade, or quantity discounts or rebates (as allowed under applicable law); sales
tax, use tax, tariff, import/export duties or other excise taxes imposed on particular sales (except for value-added and income
taxes imposed on the sales of Licensed Product in foreign countries); transportation charges; credits to customers because of rejections
or returns, or transfers of Licensed Products without charge for charitable, promotional, non-clinical, clinical research or regulatory
purposes. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate of Licensed Product under this Agreement
without an invoice for (i) end use (but not resale) by the Sub licensee or Affiliate shall be treated as sales by LICENSEE at list
price of LICENSEE, or (ii) resale by a Sublicensee or an Affiliate shall be treated as sales at the list price of the Sublicensee
or Affiliate.

 

1.17         
“New Product” means new pharmaceutical and other products that are not Excluded Products.

 

1.18         
“Patent Costs” means all out-of-pocket expenses, for the preparation, filing, prosecution, and maintenance
of all Ex-America patents and patent applications included in Patent Rights. Patent Costs shall also include out-of-pocket expenses
for patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue,
interference, and opposition activities related to patents or applications in Patent Rights.

 

1.19         
“Patent Rights” means UNIVERSITY’s rights in any of the following: the Ex-America patent applications
and patents deriving from the US patent application (serial number 09/569,466, titled “MACROMOLECULAR CARRIER FOR DRUG AND
DIAGNOSTIC AGENT DELIVERY”) disclosing and claiming the Invention, filed by Inventor and assigned to UNIVERSITY; and continuing
applications thereof including divisions, substitutions, and continuations-in-part (but only to the extent the claims thereof are
entirely supported in the specification and entitled to the priority date of the parent application); any patents issuing on said
applications including reissues, reexaminations and extensions.

 

    	 	4	 

     

    

 

1.20         
"Relevant Regulatory Agency" means (a) the FDA or an equivalent regulatory agency in the United States
or (b) any equivalent agency or governmental authority in any country or other jurisdiction outside the United States that has
responsibility for granting any licenses or approvals necessary for the marketing and sale of a Licensed Product or License Service
in such country or other jurisdiction including, without limitation, any supra-national agency such as the "European Medicines
Agency" (EMA).

 

1.21         
“Sponsor’s Rights” means all the applicable provisions of any license to the United States
Government executed by UNIVERSITY and the overriding obligations to the US Government under 35 U.S.C. §§ 200-212
and applicable governmental implementing and the overriding obligations to NIH under the sponsorship agreement with the same.

 

1.22         
“Sublicense” means an agreement into which LICENSEE enters with a third party that is not, at the
time of execution of such Sublicense agreement, an Affiliate of LICENSEE for the purpose of (i) granting certain rights; (ii) granting
an option to certain rights; or (iii) forbearing the exercise of any rights, in each case, granted to LICENSEE under this Agreement.
“Sublicensee” means a third party with whom LICENSEE enters into a Sublicense.

 

1.23         
“Sublicense Fees” means all upfront fees, milestone payments and similar license fees received by
LICENSEE from its Sublicensees in consideration for the grant of a Sublicense, but excluding:

 

		(a)	any royalty payments;

 

		(b)	payments for equity or debt securities of LICENSEE (except to the extent such payments exceed the fair market value of such
securities upon date of receipt, in which case such premiums over fair market value shall be deemed to be “Sublicense
Fees”);

 

		(c)	research or development funding to be applied directly to the future research

and/or development of Licensed Products provided, however that such payments shall not include executive and clerical salaries,
legal costs (other than Patent Costs) or other costs not directly related to research,

 

		(d)	payments and reimbursement to LICENSEE of Patent Costs paid to

UNIVERSITY by LICENSEE with respect to the filing, preparation, prosecution or maintenance of the Patent Rights; and

 

		(e)	milestone payments attributable to the achievement of any of the milestone events set forth in Section 3.1(c).

 

1.24         
“Technology” means the written technical information relating to the Invention, excluding personal
health information (PHI) and personal identity information (PII), which the Inventor has and may provide to LICENSEE during the
Term of this Agreement.

 

1.25         
“Term” means on a country-by-country basis, the period of time beginning on the Effective Date and
(i) ending on the third anniversary of the expiration date of last to expire valid claim in the Patent Rights covering the Licensed
Product where no patent extension is granted, (ii) ending on the third anniversary of the expiration date of the last-to-expire
patent extension covering the Licensed Product where patent extension is granted, or (iii) three (3) years from the first sale
of a Licensed Product where no Patent Rights exist but Technology is utilized.

 

    	 	5	 

     

    

 

1.26         
“Territory” means (i) Ex-America with respect to Ex-America Products and (ii) worldwide, with respect
to New Products, in each case to the extent this license may legally be granted.

 

1.27         
“Third Party” means any individual or entity other than LICENSEE or UNIVERSITY or an Affiliate of
LICENSEE or UNIVERSITY.

 

Article
2. GRANTS

 

2.1             
License. Subject to the limitations set forth in this Agreement and Sponsor’s Rights, UNIVERSITY hereby grants
to LICENSEE, and LICENSEE hereby accepts, a license under Patent Rights to make and have made, to use and have used, to sell and
have sold, to offer for sale, and to import Licensed Products and to practice Licensed Methods and to use Technology, in the Field
within the Territory and during the Term.

 

The license granted herein is exclusive
(other than with respect to Cardinal Health, its Affiliates, sublicensees or distributors (each, a "CAH Entity")
or any other third party that is granted any Patent Rights by any CAH Entity pursuant to the Cardinal Agreement) for Patent Rights
and non-exclusive for Technology.

 

2.2             
Sublicense.

 

		(a)	The license granted in Section 2.1 includes the right of LICENSEE to grant sublicenses to third parties and Affiliates during
the Term, through multiple tiers, but only for as long as the license from UNIVERSITY is exclusive.

 

		(b)	With respect to Sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall:

 

		(i)	not receive, or agree to receive, anything of value in lieu of cash as consideration from a third party under a Sublicense
granted pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY;

 

		(ii)	to the extent applicable, include all of the rights of and obligations due to UNIVERSITY (and, if applicable, the Sponsor’s
Rights) and contained in this Agreement;

 

		(iii)	promptly provide UNIVERSITY with a copy of each Sublicense issued, and

 

		(iv)	collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and
deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees.

 

    	 	6	 

     

    

 

		(c)	Upon early termination of this Agreement for any reason (but not expiration as provided in Section 1.25), UNIVERSITY, at its
sole discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all Sublicenses.

 

2.3             
Reservation of Rights. UNIVERSITY reserves the right to:

 

		(a)	use the Invention, Technology and Patent Rights for educational and research purposes;

 

		(b)	subject to the provisions of Article 10.2, publish or otherwise disseminate any information about the Invention and Technology
at any time; and

 

		(c)	allow other nonprofit institutions to use and publish or otherwise disseminate any information about Invention, Technology
and Patent Rights for educational and research purpose.

 

Article
3. CONSIDERATION

 

3.1             
Fees and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under
this Agreement are partial consideration for the license granted herein to LICENSEE under Technology, and Patent Rights. LICENSEE
shall pay UNIVERSITY:

 

		(a)	a license amendment fee of twenty-five thousand dollars (US$25,000) payable within thirty (30) days of the Effective Date;

 

		(b)	license maintenance fees of twenty-five thousand dollars (US$25,000) per year, payable annually, (already satisfied by LICENSEE)
and that LICENSEE’s obligation to pay this fee has ended on the date of the first commercial sale of a Licensed Product in
the Territory;

 

		(c)	milestone payments in the amounts set forth below within forty-five (45) days after the achievement of each of the following
events:

 

	 	Amount in US dollars	Event
	A	$[*]	Commencement of phase 2 trial for melanoma.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone A was made in full on Aug 2006.
	B	$[*]	Commencement of phase 2 trial for breast cancer.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone B was made in full on Aug 2006.
	C	$[*]	Earlier of commencement for any cancer that is not melanoma, breast, colorectal, stomach, or cervical or regulatory approval allowing sales of Licensed Product for cancer other than melanoma, breast, colorectal, stomach, or cervical.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone C was made in full on April 2009.

 

 

    	 	7	 

     

    

 

	 	Amount in US dollars	Event
	D	$[*]	Completion of phase 3 trial for melanoma.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone D was made in full on April 2009.
	E	$[*]	Completion of phase 3 trial for breast cancer.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone E was made in full on April 2009.
	F	$[*]	Submission of application for regulatory approval.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone F was made in full on December 2011.
	G	$[*]	US regulatory clearance granted allowing sales of Licensed Product independent of disease type, or for two or more disease types, or to be substituted by H and I. UNIVERSITY and LICENSEE acknowledge that the payment for milestone G was made in full in 2013.
	H	$[*]	US regulatory clearance granted allowing sales of Licensed Product for the first disease type.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone H was satisfied by payment of milestone G.
	I	$[*]	US regulatory clearance granted allowing sales of Licensed Product for the second disease type.  UNIVERSITY and LICENSEE acknowledge that the payment for milestone I was satisfied by payment of milestone G.
	J	$[*]	Regulatory clearance allowing sales of Licensed Product in any EPO Member State or Japan independent of disease type, for two or more disease types, or to be substituted by K and L.

 

 

    	 	8	 

     

    

 

	 	Amount in US dollars	Event
	K	$[*]	Regulatory clearance allowing sales of Licensed Product in any EPO Member State or Japan for the first disease type.
	L	$[*]	Regulatory clearance allowing sales of Licensed Product in any EPO Member State or Japan for the second disease type.

 

		(d)	Earned royalty on Net Sales of Licensed Products by LICENSEE and/or Affiliate, or any combination thereof when (A) the License
Product is manufactured in a country with Patent Rights and sold in a country with Patent Rights, (B) the License Product is manufactured
in a country with Patent Rights and sold in a country without Patent Rights, or (C) when the Licensed Product is manufactured in
a country without Patent Rights and imported to a country with Patent Rights:

 

3.1(d) Royalty Rate Table

 

	Percent of earned royalty	 
	[*]%	For accumulated Net Sales by LICENSEE, Affiliate, or any combination thereof, to, including without limitation, End User and/or Distributor, less than or equal to [*] US dollars ($[*])
	[*]%	For accumulated Net Sales by LICENSEE, Affiliate, or any combination thereof, to, including without limitation, End User and/or Distributor, greater than [*] US dollars ($[*]) but less than or equal to [*] US dollars ($[*])
	[*]%	For accumulated Net Sales by LICENSEE, Affiliate, or any combination thereof, to, including without limitation, End User and/or Distributor, greater than [*] US dollars ($[*])

 

provided, however, that the earned royalty due on
Net Sales of:

 

    	 	9	 

     

    

 

		(i)	Licensed Products sold within three (3) years after the expiration date of the Patent Rights or the extension of the Patent
Rights, and that would have infringed Patent Rights prior to expiration or extension of the Patent Rights will be deemed to be
Licensed Product as consideration of the use of the Technology with a royalty during the first year of that three year period due
at a royalty rate reduced to [*] percent ([*]%) of the rates listed above, during the second year of that three year period due
at a royalty rate reduced to [*] percent ([*]%) of the rates listed above and during the third year of that three year period due
at a royalty rate reduced to [*] percent ([*]%) of the rates listed above;

 

		(ii)	Licensed Products manufactured in a country without Patent Rights and sold in a country without Patent Rights will be deemed
to be Licensed Product as consideration of the use of the Technology with a royalty rate of [*] percent ([*]%) of 3.1(d) Royalty
Rate Table;

 

		(iii)	Licensed Product sold to Distributor(s), shall be based on the gross amounts invoiced to Distributor(s) for Licensed Products
and the value of any other consideration (for example, but not by way of limitation, payments for Licensed Product, transfer cost,
a division of revenue, milestone payments, profits, or an option to purchase stock or other equity interest) received by LICENSEE,
Sublicensee, Affiliate, or any combination thereof, less the sum of the following actual and customary deductions where applicable
and separately listed: cash, trade, or quantity discounts or rebates (as allowed under applicable law); sales tax, use tax, tariff,
import/export duties or other excise taxes imposed on particular sales (except for value-added and income taxes imposed on the
sales of Licensed Product in foreign countries); transportation charges; credits because of rejections or returns;

 

		(iv)	Combination Product by LICENSEE and/or its Affiliate(s) shall be calculated as below:

 

Earned Royalties due UNIVERSITY= [A/(A+B)] x applicable
Royalty Rate on Net Sales of the Licensed Products applicable in (i), (ii), or (iii) x Net Sales of Combination Product, where:

 

A is the separate average sales price of the Licensed
Product or Licensed Product components during the period to which the royalty calculation applies; and B is the average sales price
of the separately listed sale prices of the individual products or product components included in such Combination Product that
are not Licensed Products during the period to which the royalty calculation applies. If LICENSEE does not separately sell the
Licensed Product or the B product or product components used in Combination Product, the purchase price paid by LICENSEE in the
procurement of said products or product components shall be used. For any products in B for which LICENSEE has reduced its earned
royalties payable to UNIVERSITY under 3.1(d)(v), this provision shall not apply.

 

    	 	10	 

     

    

 

		(v)	in the event LICENSEE or Affiliate is required to pay royalties to one or more third parties for patent rights necessary to
make, use or sell Licensed Products, LICENSEE may deduct $[*] from the earned royalties payable to UNIVERSITY for every $[*] LICENSEE
or Affiliate actually pays to said third parties; and

 

		(vi)	in no event shall the amount payable to UNIVERSITY in any calendar quarter be less than [*] percent ([*]%) of the amount without
the deductions allowable under 3.1 (d) (iv) and/or 3.1 (d) (v);

 

		(e)	the applicable percentage (“Applicable Percentage” or “AP”) according to the following
schedules of all Sublicense Fees received by LICENSEE from its Sublicensees that are not earned royalties according to the following
schedules::

 

	 	Time of Sublicense Grant	AP(%)
	A	[*]	[*]%
	B	[*]	[*]%
	C	[*]	[*]%
	D	[*]	[*]%
	E	[*]	[*]%
	F	[*]	[*]%
	G	[*]	[*]%
	H	[*]	[*]%

 

		(f)	on each and every Sublicense royalty payment received by LICENSEE from its Sublicensees on Net Sales of Licensed Product by
Sublicensee, royalties based on the royalty rate of (i) [*] percent ([*]%) as applied to Net Sales (defined in 1.16) of Sublicensee
to End User, and (ii) [*] percent ([*]%) as applied to Net Sales (defined in 3.1(d)(iii)) of Sublicensee to Distributor;

 

		(g)	beginning with the calendar year of first commercial sale of the first Licensed Product by LICENSEE, its Sublicensee, or an
Affiliate, if the total earned royalties paid by LICENSEE under Paragraphs 3.1(d) and (f) to UNIVERSITY in any such year cumulatively
amounts to less than twenty-five thousand Dollars ($25,000) (“minimum annual royalty”), LICENSEE shall pay to UNIVERSITY
on or before February 28 following the last quarter of such year the difference between the minimum annual royalty and the total
earned royalty paid by LICENSEE for such year under Paragraphs 3. l(d) and (f); provided, however, that for the year of first commercial
sale of the first Licensed Product, the amount of minimum annual royalty payable shall be pro-rated for the number of months remaining
in that calendar year.

 

    	 	11	 

     

    

 

All fees and royalty payments specified in Paragraphs
3.1(a) through 3.1(g) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY
as noted in Paragraph 10.1.

 

For purposes of this Section 3 .1, if any rights to
develop, manufacture or commercialize Licensed Products are granted by LICENSEE to an Affiliate and thereafter such party ceases
to be an Affiliate of LICENSEE, such party will not be deemed to be a Sublicensee hereunder, and the exercise of any such rights
granted to such party will be remain subject to the provisions of this Section 3.1 as if such party were an Affiliate and remains
under a Sublicense.

 

		(h)	As full and complete consideration for the issuance of the License and the UNIVERSITY entering the Cardinal Agreement, UNIVERSITY
will within 30 days of the effective date of the License receive a warrant to purchase One Million (1,000,000) shares of fully
paid and non-assessable shares of Common Stock of LICENSEE, subject to the provisions and upon the terms set forth in Exhibit A
(Warrant to Purchase Shares of Common Stock), (the "Warrant"). The Warrant and shares issuable upon exercise of the Warrant
will be issued in the UNIVERSITY's street name, Shellwater & Company. The Regents receipt of the Warrant is subject to approval
of UNIVERSITY's Office of the President.

 

3.2             
Patent Costs. LICENSEE shall reimburse UNIVERSITY for all past (prior to the Effective Date) and future (on or after
the Effective Date) Patent Costs within thirty (30) days following the date an itemized invoice is sent from UNIVERSITY to LICENSEE.

 

3.3             
Due Diligence.

 

		(a)	LICENSEE shall, either directly or through its Affiliate(s) or Sublicensee(s) to:

 

		(i)	diligently proceed with the development, manufacture and sale of Licensed Products;

 

		(ii)	use Commercially Reasonable Efforts to diligently market Licensed Products, in countries for which it is Commercially Reasonable
to do so, (A) in such countries where adequate pricing and reimbursement are required to benefit the entire Licensed Product franchise,
within six (6) months of receiving all regulatory approvals including pricing and reimbursement; or (B) in such countries where
pricing and reimbursement are determined not necessary to benefit the entire Licensed Product franchise, within six (6) months
of receiving regulatory approval;

 

		(iii)	fill the market demand for Licensed Products following commencement of marketing at any time during the term of this Agreement
and

 

		(iv)	obtain all necessary governmental approvals for the use and sale of Licensed Products in the Territory.

 

    	 	12	 

     

    

 

		(b)	If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.1(c) and 3.3(a)(i)-(iv), then UNIVERSITY shall
have the right and option to either terminate this Agreement or change LICENSEE’s exclusive license to a nonexclusive license
provided that LICENSEE has not cured such failure to perform within ninety (90) days written notice from the UNIVERSITY of said
failure. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2.

 

Article
4. REPORTS, RECORDS AND PAYMENTS

 

4.1             
Reports.

 

		(a)	Progress Reports.

 

		(i)	Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United
States, with respect to each six month period ending June 30 and December 31 during such period, LICENSEE shall report to UNIVERSITY
LICENSEE’s (and Affiliate’s and Sublicensee’s) activities for the preceding six months to develop and test all
Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within
sixty (60) days of the reporting period and include a summary of work completed, summary of work in progress, current schedule
of anticipated events or milestones, market plans for introduction of Licensed Products, and summary of resources (dollar value)
spent in the reporting period. The reports referred to in this Section 4.1(a) should be marked with the following title and case
number: “License Agreement between UCSD and Navidea Biopharmaceuticals for case SD1998-088”. Reports shall be submitted
as attachment to UCSD’s email address: tto-reports@uscd.edu.

 

		(ii)	LICENSEE shall report to UNIVERSITY the date of a first commercial sale of a Licensed Product anywhere in the Territory. Beginning
three months after Effective Date and ending on the date of first commercial sale, the UNIVERSITY may request the status of such
first commercial sale.

 

		(b)	Royalty Reports.

 

After the first commercial sale of a Licensed Product
anywhere in the Territory, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on or before February 28, May 31, August
31 and November 30 of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s)
most recently completed calendar quarter and shall show:

 

		(i)	the date of first commercial sale of a Licensed Product in each country in the Territory;

 

    	 	13	 

     

    

 

		(ii)	the gross sales, deductions as provided in Paragraph 1.16 (Net Sales), and Net Sales during the most recently completed calendar
quarter and the royalties, in US dollars, payable with respect thereto;

 

		(iii)	the number of each type of Licensed Product sold;

 

		(iv)	Sublicense Fees and royalties received during the most recently completed calendar quarter in US dollars, and the portion thereof
payable to UNIVERSITY hereunder;

 

		(v)	the method used to calculate the royalties; and

 

		(vi)	the exchange rates used.

 

If no sales of Licensed Products have been made and
no Sublicensing Revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred
to in this Section 4.1(b) should be marked with the following title and case number: “License Agreement between UCSD and
Navidea Biopharmaceuticals for case SD 1998-088”. Reports shall be submitted as attachment to UCSD’s email address:
tto-reports@ucsd.edu.

 

4.2             
Records & Audits.

 

		(a)	LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed
Products manufactured, used, and sold, and Sublicense Fees received under this Agreement. Such records shall be retained by LICENSEE
for at least five (5) years following a given reporting period.

 

		(b)	Upon five (5) business days prior notice to LICENSEE all records shall be available during normal business hours for inspection
at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY
and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments or other compliance
issues. Such inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports
and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting
and underpayment in excess of five percent (5%) for any twelve-month (12-month) period, then LICENSEE shall pay the cost of the
audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest
charge at a rate of ten percent (10%) per year. Such interest shall be calculated from the date the correct payment was due to
UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess of five percent (5%) for
any twelve-month (12-month) period, LICENSEE shall pay the difference within thirty (30) days without interest charge or inspection
cost. UNIVERSITY may only conduct one such audit per calendar year.

 

    	 	14	 

     

    

 

4.3             
Payments.

 

		(a)	All fees, reimbursements and royalties due to UNIVERSITY shall be paid in United States dollars and all checks shall be made
payable to “The Regents of the University of California”, referencing UNIVERSITY’s taxpayer identification number,
95-6006144, and sent to UNIVERSITY according to Paragraph 10.1 (Correspondence). When Licensed Products are sold in currencies
other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the country in which Licensed
Products were sold and then convert the amount into equivalent United States funds, using the exchange rate quoted in the Wall
Street Journal on the last business day of the applicable reporting period.

 

		(b)	Royalty Payments.

 

		(i)	Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

 

		(ii)	LICENSEE shall pay earned royalties quarterly on or before February 28, May 31, August 31 and November 30 of each calendar
year. Each such payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar quarter.

 

		(iii)	Royalties earned on sales occurring or under a Sublicense granted pursuant to this Agreement in any country outside the United
States shall not be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country on the
payment of royalty income, except that all payments made by LICENSEE in fulfillment of UNIVERSITY’s tax liability in any
particular country may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank
charges resulting from the transfer of such royalty payments.

 

		(iv)	If at any time legal restrictions prevent the prompt remittance of part or all royalties by LICENSEE with respect to any country
where a Licensed Product is sold or a Sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed
to UNIVERSITY into US currency and shall pay UNIVERSITY directly from its US sources of funds for as long as the legal restrictions
apply.

 

		(v)	LICENSEE shall not collect royalties from, or cause to be paid on Licensed Products sold to the account of the US Government
or any agency thereof as provided for in the license to the US Government.

 

		(vi)	In the event that any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from
which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort
and from which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim
patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from
paying any royalties that accrued before the date of such final decision, that are based on another patent or claim not involved
in such final decision, or that are based on the use of Technology.

    	 	15	 

     

    

 

 

		(vii)	Royalty payments under Article 3, recoveries and settlements under Article 5, and royalty reports under 4.1(b) shall be rendered
for any and all Licensed Products even if due after expiration of the Agreement.

 

		(c)	Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall
pay to UNIVERSITY interest charges at a rate of ten percent (10%) per year. Such interest shall be calculated from the date payment
was due until actually received by UNIVERSITY.

 

(d)       No
withholding. LICENSEE shall not reduce or withhold any payments otherwise due under this Agreement on account of any dispute
related to the Cardinal Agreement, the Cardinal/Navidea Agreement or any action whatsoever between LICENSEE and Cardinal Health,
its Affiliates, successors or assigns.

 

Article
5. PATENT MATTERS

 

5.1             
Patent Prosecution and Maintenance.

 

		(a)	Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.2, UNIVERSITY shall diligently prosecute
and maintain the United States and, Ex-America patents, and applications in Patent Rights using counsel of its choice. For purposes
of clarity, if LICENSEE is not current in reimbursing UNIVERSITY for such Patent Costs, UNIVERSITY shall have no obligation to
incur any new Patent Costs under this Agreement or to further prosecute Patent Rights or file any new patents under Patent Rights.
UNIVERSITY shall provide LICENSEE with copies of all relevant documentation relating to such prosecution and LICENSEE shall keep
this documentation confidential. The UNIVERSITY’s counsel shall take instructions only from UNIVERSITY, and all patents and
patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY shall in any event control all patent filings
and all patent prosecution decisions and related filings (e.g. responses to office actions) shall be at UNIVERSITY’s final
discretion (prosecution includes, but is not limited to, interferences, oppositions and any other inter partes matters originating
in a patent office).

 

		(b)	UNIVERSITY shall consider amending any patent application in Patent Rights to include claims reasonably requested by LICENSEE
to protect the products contemplated to be sold by LICENSEE under this Agreement.

 

		(c)	LICENSEE may elect to terminate its reimbursement obligations with respect to any patent application or patent in Patent Rights
upon three (3) months’ written notice to UNIVERSITYand Cardinal Health. UNIVERSITY shall use reasonable efforts to curtail
further Patent Costs for such application or patent when such notice of termination is received from LICENSEE. UNIVERSITY, in its
sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall
have no further license with respect thereto. Non-payment of any portion of Patent Costs or Anticipated Costs with respect to any
application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with respect
to such application or patent. UNIVERSITY is not obligated at any time to file, prosecute, or maintain Patent Rights in a country,
where, for that country’s patent application LICENSEE is not paying Patent Costs, or to file, prosecute, or maintain Patent
Rights to which LICENSEE has terminated its license hereunder.

 

    	 	16	 

     

    

 

		(d)	LICENSEE shall apply for an extension of the term of any patent in Patent Rights if appropriate under the Drug Price Competition
and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this law. LICENSEE shall prepare
all documents for such application, and UNIVERSITY shall execute such documents and take any other additional action as LICENSEE
reasonably requests in connection therewith.

 

5.2             
Patent Infringement and Defense.

 

		(a)	In the event that UNIVERSITY (to the extent of the actual knowledge of the licensing professional responsible for the administration
of this Agreement) or LICENSEE learns of infringement of potential commercial significance of any patent licensed under this Agreement
or any notice of any legal or administrative action by any third party against a Patent Right, including any oppositions, interferences,
derivation, revocation, reexamination, inter partes review, post-grant, nullity action, compulsory license proceeding, or
declaratory judgment action ("Invalidity Action"), the knowledgeable party will provide the other (i) with written
notice of such infringement or Invalidity Action within fifteen (15) days and (ii) with any evidence of such infringement available
to it (the “Infringement/Invalidity Notice”). Subject to Sections 5.2(b) and 5.2(c), during the period in which,
and in the jurisdiction where, LICENSEE has exclusive rights under this Agreement, (other than with respect to Cardinal Health)
neither UNIVERSITY nor LICENSEE will notify a third party (including the infringer) of infringement or put such third party on
notice of the existence of any Patent Rights without first obtaining consent of the other. If LICENSEE notifies a third party of
infringement or puts such third party on notice of the existence of any Patent Rights with respect to such infringement without
first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued in declaratory judgment, UNIVERSITY shall have the right
to terminate this Agreement immediately without the obligation to provide sixty (60) days’ notice as set forth in Paragraph
7.1. Both UNIVERSITY and LICENSEE will use their diligent efforts to cooperate with each other to terminate such infringement or
resolve the Invalidity Action without litigation.

 

    	 	17	 

     

    

 

		(b)	If the infringing activity of potential commercial significance by the infringer has not been abated or the Invalidity Action
has not been resolved to the reasonable satisfaction of the parties within ninety (90) days following the date of the Infringement/Invalidity
Notice, subject to LICENSEE'S obligations to Cardinal Health under the Cardinal/Navidea Agreement, LICENSEE may institute suit
for patent infringement against the infringer or defend the relevant Patent Rights against the Invalidity Action (as applicable).
UNIVERSITY may voluntarily join such suit at its own expense, but with respect to patent infringement, may not thereafter commence
suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered
in that suit. LICENSEE may not join UNIVERSITY in a suit initiated by LICENSEE without UNIVERSITY’S prior written consent.
If, in a suit initiated by LICENSEE, UNIVERSITY is involuntarily joined other than by LICENSEE, LICENSEE will pay any costs incurred
by UNIVERSITY arising out of such suit, including but not limited to, any legal fees of counsel that UNIVERSITY selects and retains
to represent it in the suit.

 

		(c)	If, within a hundred and twenty (120) days following the date the Infringement/Invalidity Notice takes effect, the infringing
activity of potential commercial significance by the infringer has not been abated or the Invalidity Action has not been resolved
to the reasonable satisfaction of the parties and if neither LICENSEE or Cardinal Health has brought suit against the infringer
or relevant third party, UNIVERSITY may institute suit for patent infringement against the infringer or defend the relevant Patent
Rights against the Invalidity Action (as applicable). If UNIVERSITY institutes such suit, LICENSEE may not join such suit without
UNIVERSITY’S consent and may not thereafter commence suit against the infringer for the acts of infringement that are the
subject of UNIVERSITY’S suit or any judgment rendered in that suit.

 

		(d)	Notwithstanding anything to the contrary in this Agreement, with respect to patent infringement only in the event that the
infringement or potential infringement pertains to an issued patent included within the Patent Rights and written notice is given
under any statute expediting litigation (e.g. the Drug Price Competition and Patent Term Restoration Act of 1984 and/or foreign
counterparts of this Law) (“Act”), then the party in receipt of such notice under the Act (in the case of UNIVERSITY
to the extent of the actual knowledge of the licensing officer responsible for the administration of this Agreement) shall provide
the Infringement/Invalidity Notice to the other party promptly. If the time period is such that the LICENSEE will lose the right
to pursue legal remedy for infringement by not notifying a third party or by not filing suit, the notification period and the time
period to file suit will be accelerated to within forty-five (45) days of the date of such notice under the Act to either party.

 

		(e)	Any recovery or settlement received in connection with any suit under this Agreement will first be shared by UNIVERSITY and
LICENSEE equally to cover the litigation costs each incurred, and next shall be paid to UNIVERSITY or LICENSEE to cover any litigation
costs it incurred in excess of the litigation costs of the other. In any suit initiated by LICENSEE, any recovery in excess of
litigation costs will be shared between LICENSEE and UNIVERSITY as follows: (i) for any recovery other than amounts paid for willful
infringement: (A) UNIVERSITY will receive fifteen percent (15%) of the recovery if UNIVERSITY was not a party in the litigation
and did not incur any litigation costs; (B) UNIVERSITY will receive twenty-five percent (25%) of the recovery if UNIVERSITY was
a party in the litigation, but did not incur any litigation costs, including the provisions of Paragraph 5.2(b) above, or (C) UNIVERSITY
will receive fifty percent (50%) of the recovery if UNIVERSITY incurred any litigation costs in connection with the litigation;
and (ii) for any recovery for willful infringement, UNIVERSITY will receive fifty percent (50%) of the recovery. In any suit initiated
by UNIVERSITY, any recovery in excess of litigation costs will belong to UNIVERSITY. UNIVERSITY and LICENSEE agree to be bound
by all determinations of patent infringement, validity, and enforceability (but no other issue) resolved by any adjudicated judgment
in a suit brought in compliance with this Section 5.2.

 

    	 	18	 

     

    

 

		(f)	Any agreement made by LICENSEE for purposes of settling litigation or other dispute shall comply with the requirements of Section
2.2 (Sublicenses) of this Agreement.

 

		(g)	Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who
initiated the suit (unless such suit is being jointly prosecuted by the parties).

 

		(h)	Any litigation proceedings will be controlled by the party bringing the suit, except that UNIVERSITY may be represented by
counsel of its choice in any suit brought by LICENSEE.

 

5.3             
Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under the terms of this Agreement, or their
containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for all monetary and legal liabilities
arising from or caused by (i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent
marking.

 

Article
6. GOVERNMENTAL MATTERS

 

6.1             
Governmental Approval or Registration. If this Agreement or any associated transaction is required by the law of any
nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so.
LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United States or foreign government reporting
or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket
costs associated with such reporting or approval process.

 

6.2             
Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer
of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic
in Arms Regulations and the Export Administration Regulations.

 

    	 	19	 

     

    

 

6.3             
Preference for United States Industry. If LICENSEE sells a Licensed Product or Combination Product in the US, LICENSEE
shall manufacture said product substantially in the US. Notwithstanding the foregoing, at LICENSEE’s request, UNIVERSITY
will reasonably cooperate with LICENSEE in seeking a waiver to the requirement for substantial manufacture in the United States
according to 35 U.S. CODE § 204. To the extent such waiver if granted, LICENSEE shall comply with the terms granted in
the waiver.

 

Article
7. TERMINATION OR EXPIRATION OF THE AGREEMENT

 

7.1             
Termination by UNIVERSITY.

 

		(a)	If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice
of Default”) to LICENSEE. If LICENSEE fails to cure the default within ninety (90) days of the Notice of Default, UNIVERSITY
may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”)
to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date
of that notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall
not impair any accrued right of UNIVERSITY. During the term of any such Notice of Default or period to cure, to the extent the
default at issue is a failure to pay past or ongoing Patent Costs as provided for under this Agreement, UNIVERSITY shall have no
obligation to incur any new Patent Costs under this Agreement and shall have no obligation to further prosecute Patent Rights or
file any new patents under Patent Rights.

 

		(b)	This Agreement will terminate immediately, without the obligation to provide ninety (90) days’ notice as set forth in
Paragraph 7.1(a), if LICENSEE files a claim including in any way the assertion that any portion of UNIVERSITY’s Patent Rights
is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at the
written urging of the LICENSEE.

 

		(c)	This Agreement shall automatically terminate without the obligation to provide ninety (90) days’ notice as set forth
in Paragraph 7.1(a) upon the filing of a petition for relief under the United States Bankruptcy Code by or against the LICENSEE
as a debtor or alleged debtor.

 

7.2             
Termination by LICENSEE.

 

		(a)	LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written notice
to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement.

 

    	 	20	 

     

    

 

		(b)	Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement
prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective.
Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.

 

7.3             
Survival on Termination or Expiration. The following Paragraphs and Articles shall survive the termination or expiration
of this Agreement:

 

		(a)	Article 4 (REPORTS, RECORDS AND PAYMENTS);

 

		(b)	Paragraph 7.3 (Survival on Termination or Expiration);

 

		(c)	Paragraph 7.4 (Disposition of Licensed Products on Hand);

 

		(d)	Paragraph 7.5 (Fully-Paid License);

 

		(e)	Article 8 (LIMITED WARRANTY AND INDEMNIFICATION);

 

		(f)	Article 9 (USE OF NAMES AND TRADEMARKS);

 

		(g)	Section 10.2 hereof (Secrecy);

 

		(h)	Paragraph 10.5 (Failure to Perform); and

 

		(i)	Paragraph 10.6 (Governing Laws).

 

7.4             
Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of all previously
made or partially made Licensed Product within a period of one hundred and twenty (120) days of the effective date of such termination
provided that the sale of such Licensed Product by LICENSEE, its Sub licensees, or Affiliates shall be subject to the terms of
this Agreement, including but not limited to the rendering of reports and payment of royalties required under this Agreement.

 

7.5             
Fully-Paid License. Upon expiration of the Term on a country-by-country basis (but not termination under Section 7.1
or 7.2) the license granted to LICENSEE in Section 2.1 shall become a perpetual, irrevocable, fully-paid license.

 

Article
8. LIMITED WARRANTY AND INDEMNIFICATION

 

8.1             
Limited Warranty.

 

		(a)	UNIVERSITY warrants to the LICENSEE that it has the lawful right to grant this license. This warranty does not include Patent
Rights to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventor to third parties.

 

		(b)	The license granted herein and the associated Technology are provided “AS IS” and without WARRANTY OF MERCHANTABILITY
or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or
warranty that the Licensed Product, Licensed Method or the use of Patent Rights or Technology will not infringe any other patent
or other proprietary rights.

 

    	 	21	 

     

    

 

		(c)	UNIVERSITY WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED
DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES
SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF
ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES,
JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S
INVENTOR TO THIRD PARTIES.

 

		(d)	Nothing in this Agreement shall be construed as:

 

		(i)	a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights;

 

		(ii)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement
is or shall be free from infringement of patents of third parties;

 

		(iii)	an obligation to bring or prosecute actions or suits against third parties for patent infringement or misappropriation of Technology
except as provided in Section 5.2 hereof;

 

		(iv)	conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights
as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or

 

		(v)	an obligation to furnish any know-how not provided in Patent Rights and Technology; or

 

		(vi)	an obligation to update Technology.

 

8.2             
Indemnification.

 

		(a)	LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers, employees,
and agents; the sponsors of the research that led to the Invention; and the inventor of patents or patent applications under Patent
Rights, and their employers; against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from, or arising
out of, the exercise of this license or any Sublicense, including any disputes arising under the Cardinal/Navidea Agreement. This
indemnification will include, but will not be limited to, any product liability.

 

    	 	22	 

     

    

 

		(b)	LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain,
keep in force and maintain insurance or an equivalent program of self insurance as follows:

 

		(i)	comprehensive or commercial general liability insurance (contractual liability included) with limits of at least: (A) each
occurrence, five million dollars (US$5,000,000); (B) products/completed operations aggregate, ten million dollars (US$10,000,000);
(C) personal and advertising injury, five million dollars (US$5,000,000); and (D) general aggregate (commercial form only), ten
million dollars (US$10,000,000). If the above insurance is written on a claims-made form, it shall continue for three (3) years
following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding
with the Effective Date

 

		(ii)	Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and

 

		(iii)	the coverage and limits referred to above shall not in any way limit the liability of LICENSEE.

 

		(c)	LICENSEE shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates
shall: (i) provide for thirty (30) day advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY
has been endorsed as an additionally insured party under the coverage referred to above; and (iii) include a provision that the
coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program
of self-insurance carried or maintained by UNIVERSITY.

 

		(d)	UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY
intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of
any claims under this Article. LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY’s written consent,
where (i) such settlement would include any admission of liability or admission of wrong doing on the part of the indemnified party,
(ii) such settlement would impose any restriction on UNIVERSITY/indemnified party’s conduct of any of its activities, or
(iii) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims
that are the subject matter of the settled claim.

 

    	 	23	 

     

    

 

Article
9. USE OF NAMES AND TRADEMARKS

 

9.1             
Except as provided in 9.3, nothing contained in this Agreement confers any right to use in advertising, publicity, or
other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction,
abbreviation or simulation of any of the foregoing). Unless required by law, the use by LICENSEE of the name, “The Regents
of the University of California” or the name of any campus of the University of California in advertising, publicity, or
other promotional activities is prohibited, without the express written consent of UNIVERSITY.

 

9.2             
UNIVERSITY may disclose to the Inventor the terms and conditions of this Agreement upon their request. If such disclosure
is made, UNIVERSITY shall request the Inventor not disclose such terms and conditions to others.

 

9.3             
UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties,
but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by
law to do so, such as under the California Public Records Act. LICENSEE hereby grants permission for UNIVERSITY (including UCSD)
to include LICENSEE’s name and a link to LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and
on UNIVERSITY’s (including UCSD’s) websites that showcase technology transfer-related stories.

 

Article
10. MISCELLANEOUS PROVISIONS

 

10.1         
Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have
been properly given and effective:

 

		(a)	on the date of delivery if delivered in person,

 

		(b)	five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below,
or to such other address as is designated by written notice given to the other party, or

 

		(c)	upon confirmation by recognized national overnight courier, confirmed facsimile transmission, or confirmed electronic mail,
to the following addresses or facsimile numbers of the parties.

 

If sent to LICENSEE:

Navidea Biopharmaceuticals, Inc.

5600 Blazer Parkway, Suite 200,

Dublin, OH 43017-1367

Attention: President, CEO

Phone: 614-793-7500

Fax: 614-793-7522

 

    	 	24	 

     

    

 

If sent to UNIVERSITY by mail:

University of California, San Diego

Office of Innovation & Commercialization

9500 Gilman Drive, Mail Code 0910

La Jolla, CA 92093-0910

Attention: Director

 

If sent to UNIVERSITY by overnight
delivery:

University of California, San Diego

Office of Innovation & Commercialization

10300 North Torrey Pines Road

Torrey Pines Center North, Third Floor

La Jolla, CA 92037

Attention: Director

 

10.2         
Secrecy.

 

		(a)	“Confidential Information” shall mean with respect to UNIVERSITY, confidential information, including Technology,
relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, and with respect to LICENSEE,
all trade secrets or confidential or proprietary information or tangible materials provided by LICENSEE received by UNIVERSITY
hereunder (including any reports delivered pursuant to Section 4.1) in the course of its performance of its obligations hereunder,
which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall within
thirty (30) days of such disclosure be reduced to writing by the disclosing party and sent to the receiving party.

 

		(b)	Receiving party shall:

 

		(i)	use the Confidential Information for the sole purpose of performing under the terms of this Agreement;

 

		(ii)	safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data
of a similar nature;

 

		(iii)	not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to the receiving
party by a like obligation of confidentiality) without the express written permission of the disclosing party, except that the
receiving party shall not be prevented from using or disclosing any of the Confidential Information that:

 

		(A)	the receiving party can demonstrate by written records was previously known to it;

 

		(B)	is now, or becomes in the future, public knowledge other than through acts or omissions of the receiving party;

 

    	 	25	 

     

    

 

		(C)	is lawfully obtained by the receiving party from sources independent of the disclosing party; or

 

		(D)	is required to be disclosed by law or a court of competent jurisdiction

 

		(c)	The secrecy obligations of the receiving party with respect to Confidential Information shall continue for a period ending
five (5) years from the termination date of this Agreement.

 

10.3         
Assignability. This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE
only with the written consent of UNIVERSITY. Notwithstanding anything to the contrary in the foregoing, the consent of UNIVERSITY
will not be required if the assignment by LICENSEE is either to an Affiliate or in connection with the transfer of all or substantially
all of the business of LICENSEE to which this Agreement relates, provided, further, that in each instance the assignee expressly
assumes all obligations imposed on LICENSEE by this Agreement in writing and that the LICENSEE shall notify the UNIVERSITY of such
event and inform the UNIVERSITY whether pre-assignment or preacquisition liability remain with the old LICENSEE or are assumed
by the new LICENSEE.

 

10.4         
No Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement
shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

10.5         
Failure to Perform. In the event of a failure of performance due under this Agreement and if it becomes necessary for
either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable
attorneys’ fees in addition to costs and necessary disbursements.

 

10.6         
Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA,
but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent
or patent application.

 

10.7         
Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is
rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without
limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious
labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s
obligations herein shall resume.

 

10.8         
Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to
be a part of or to affect the meaning or interpretation of this Agreement.

 

10.9         
Entire Agreement. This Agreement embodies the entire understanding of the parties and supersedes all previous communications,
representations or understandings, either oral or written, between the parties relating to the subject matter hereof.

 

    	 	26	 

     

    

 

10.10     
Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing
and signed on behalf of each party.

 

10.11     
Severability. In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement,
and this Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.

 

    	 	27	 

     

    

 

 

IN WITNESS WHEREOF, both UNIVERSITY
and LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day
and year written.

 

	NAVIDEA BIOPHARMACEUTICALS, INC.:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
	
        By:/s/ Jed A. Latkin                   

        (Signature)

         

        Name: Jed A. Latkin

         

        Title: Interim CFO & COO

         
	
        By: /s/ Rubén Flores                          

        (Signature)

         

        Name: Rubén Flores

         

        Title: Director of Commercialization

         

	Date: March 3, 2017                     	Date: January 30, 2017                          

 

 

    	 	28EX-4.2

 Exhibit 4.2 

3.050% SENIOR NOTE DUE 2022 
 THIS IS A SECURITY
IN GLOBAL FORM WITHIN THE MEANING OF THE SENIOR INDENTURE REFERRED TO HEREINAFTER. 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (THE “DEPOSITARY”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN
SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE OR
OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

TRANSFERS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF THE DEPOSITARY OR TO A SUCCESSOR THEREOF OR SUCH
SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN THE SENIOR INDENTURE REFERRED TO ON THE REVERSE HEREOF. 

THIS SECURITY IS NOT A SAVINGS ACCOUNT, DEPOSIT OR OTHER OBLIGATION OF A BANK AND IS NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENTAL AGENCY OR
INSTRUMENTALITY. 
  

			
	 CUSIP No. 14040H BL8

ISIN No. US14040HBL87

No. [            ]
	 	Principal Amount $[            ]

 CAPITAL ONE FINANCIAL CORPORATION 

3.050% SENIOR NOTES DUE 2022 

Capital One Financial Corporation, a Delaware corporation (the “Company”), for value received, hereby promises to pay to
Cede & Co. or registered assigns the principal sum of [            ] United States Dollars, at the Company’s office or agency for said purposes, on March 9, 2022 (the
“Stated Maturity”). 
 Interest Payment Dates: March 9 and September 9 

Regular Record Dates: The fifteenth calendar day (whether or not a business day) immediately preceding the relevant Interest Payment Date 

 Reference is made to the further provisions set forth on the reverse hereof, including the
definitions of certain capitalized terms. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. 

This Security shall not be valid or obligatory until the certificate of authentication hereon shall have been duly signed by the Trustee
acting under the Senior Indenture. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	         Dated:
        
	 	
            CAPITAL ONE FINANCIAL CORPORATION

  

							
	
		
	By:	 	  

		 	 Name:

		 	 Title:

 

							
	Attest By:	 	  

		 	Name:
		 	 Title:

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Securities issued under the within-mentioned Senior Indenture. 

Dated: 
  

			
	 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee

		
	By:	 	  

		 	Authorized Signatory

 REVERSE OF SECURITY 

Capital One Financial Corporation 

3.050% Senior Notes Due 2022 

This Security is one of a duly authorized issue of debt securities of the Company, of the series hereinafter specified, all issued or to be
issued under a Senior Indenture, dated as of November 1, 1996 (the “Senior Indenture”), and duly executed and delivered by the Company to The Bank of New York Mellon Trust Company, N.A., formerly known as The Bank of New York Trust
Company, N.A., as successor to Harris Trust and Savings Bank, as trustee (hereinafter, the “Trustee”). Reference to the Senior Indenture and the Officers’ Certificate thereunder establishing the terms of this Security is hereby made
for a description of the respective rights and duties thereunder of the Trustee, the Company and the Holders of the Securities. This Security is one of a series designated as the “3.050% Senior Notes Due 2022” of the Company (hereinafter
called the “Notes”), issued under the Senior Indenture. Each Holder by accepting a Note, agrees to be bound by all terms and provisions of the Senior Indenture, as amended from time to time, applicable to the Notes. 

Neither the Senior Indenture nor the Notes limit or otherwise restrict the amount of indebtedness which may be incurred or other securities
which may be issued by the Company. The Notes issued under the Senior Indenture are direct, unsecured obligations of the Company and will mature on March 9, 2022. The Notes rank on parity with all other unsecured, unsubordinated indebtedness of
the Company. 
 The Company promises to pay interest on the principal amount of this Security at the rate of 3.050% per annum. The
Company will pay interest semi-annually in arrears on March 9 and September 9 of each year (each, an “Interest Payment Date”), commencing on September 9, 2017. Interest on this Security will accrue from March 9, 2017 or
from the most recent March 9 or September 9, as the case may be, to which interest on the Notes has been paid or duly provided for, until payment of said principal sum has been made or duly provided for. Interest on the Notes will be
computed on the basis of a 360-day year of twelve 30-day months. The Company will pay interest to the Person in whose name this Security is registered at the close of business on the fifteenth calendar day (whether or not a business day) immediately
preceding the relevant Interest Payment Date, except that the Company will pay the interest payable at the Stated Maturity of this Security to the Person or Persons to whom principal is payable. The Company will pay interest in such coin or currency
of the United States of America as at the time of payment shall be legal tender for the payment of public and private debts. The Company will make payments in respect of Notes in global form (including principal and interest) to the Holder thereof
or a nominee of the Holder, by wire transfer of immediately available funds as of the close of business on the date such payments are due. 

If the Company defaults in the payment of interest due on any Interest Payment Date after taking into account any applicable grace period,
such defaulted interest shall be paid as set forth in the Senior Indenture. 
 The Notes are not entitled to any sinking fund. 

 The Notes are subject to defeasance pursuant to Section 402 of the Senior Indenture. 

The Notes are not convertible into common stock of the Company. 

At any time after February 9, 2022 (the “Redemption Date”), the Notes will be redeemable at the option of the Company, upon not
less than 15 nor more than 45 days’ prior notice given to the holders of the Notes to be redeemed, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus in each case accrued and unpaid interest to the
Redemption Date. 
 If money sufficient to pay the redemption price of and accrued interest on the Notes (or portions thereof) to be
redeemed on the Redemption Date is deposited with the Trustee on or before the Redemption Date and certain other conditions are satisfied, then on and after the Redemption Date, interest will cease to accrue on such Notes (or such portion thereof)
called for redemption and such Notes will cease to be outstanding. If the Redemption Date is not a business day, the Issuer will pay the redemption price on the next business day without any interest or other payment due to the delay. 

If fewer than all of the Notes are to be redeemed, the Depository will select the Notes for redemption on a pro rata basis, by lot or by such
other method in accordance with the procedures of the Depository. No Notes of $1,000 or less will be redeemed in part. 
 In case an Event
of Default shall have occurred and is continuing with respect to the Notes, the principal hereof may be declared, and upon such declaration shall become, due and payable, in the manner, with the effect and subject to the conditions provided in the
Senior Indenture. The Senior Indenture provides that in certain circumstances such declaration and its consequences may be waived by the Holders of not less than a majority in aggregate principal amount of the Notes then Outstanding. However, any
such consent or waiver by the Holder shall not affect any subsequent default or impair any right consequent thereon. 
 The Senior Indenture
permits the Company and the Trustee, without the consent of the Holders of the Notes for certain situations and with the consent of not less than two-thirds of the Holders in aggregate principal amount of the Outstanding Notes of each series
affected by such supplemental indenture in other situations, to execute supplemental indentures adding to, modifying, or changing various provisions of, the Senior Indenture; provided that no such supplemental indenture, without the consent of the
Holder of each Outstanding Note affected thereby, shall (i) change the Stated Maturity of the principal of or any installment of interest on the Notes; (ii) reduce the principal amount thereof or the rate of interest thereon, or adversely
affect the right of repayment of any Holder; (iii) change the Place of Payment or Currency in which the principal of or interest on the Notes is payable, or impair the right to institute suit for the enforcement of any payment on or after the
Stated Maturity thereof; (iv) reduce the percentage in principal amount of the Outstanding Notes, the consent of whose Holders is required for any such supplemental indenture, or the consent of whose Holders is required for any waiver (of
compliance with certain provisions of the Senior Indenture or certain defaults thereunder and their consequences) provided for in the Senior Indenture, or reduce the requirements of Section 1504 for quorum or voting; or (v) modify any of
the provisions of Sections 902, 513 or 1008 of the Senior Indenture, except to increase any such percentage or provide that certain other provisions of the Senior Indenture cannot be modified or waived without the consent of the Holder of each
Outstanding Note affected thereby. 

 The Company may omit in any particular instance to comply with any term, provision or condition
set forth in Section 1005, 1006 or 1007 of the Senior Indenture, if before the time it would have to comply, the Holders of at least a majority in principal amount of the Outstanding Notes, by act of such Holders, either shall waive such
compliance in such instance or generally shall have waived compliance with such term, provision or condition, but no such waiver shall extend to or affect such term, provision or condition except to the extent so expressly waived, and, until such
waiver shall become effective, the obligations of the Company and the duties of the Trustee in respect of any such term, provision or condition shall remain in full force and effect. 

No reference herein to the Senior Indenture and no provision of this Security or of the Senior Indenture shall alter or impair the obligations
of the Company, which are absolute and unconditional, to pay the principal of or interest on this Security at the respective times and at the rate herein prescribed. 

The Notes are issuable in registered form without coupons in minimum denominations of $2,000 and in integral multiples of $1,000 in excess
thereof. A Holder may exchange the Notes for a like aggregate principal amount of Notes of other authorized denominations in the manner and subject to the limitations provided in the Senior Indenture. 

Upon due presentment for registration of transfer of the Notes at the office or agency for said purpose of the Company, a new Note or Notes of
authorized denominations, for a like aggregate principal amount, will be issued to the transferee as provided in the Senior Indenture. No service charge shall be made for any such transfer, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge that may be imposed in relation thereto. 
 Prior to due presentation of this Security for
registration of transfer, the Company, the Trustee, and any agent of the Company or the Trustee, may deem and treat the Holder hereof as the owner of this Security (whether or not any payment with respect to this Security shall be overdue), for the
purpose of receiving payment of principal of and (subject to the provisions of the Senior Indenture) interest hereon and for all other purposes whatsoever, whether or not any payment with respect to this Security shall be overdue, and neither the
Company, nor the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 
 No recourse shall be
had for the payment of the principal of or interest on this Security, for any claim based hereon, or otherwise in respect hereof, or based on or in respect of the Senior Indenture or any indenture supplemental thereto, or because of the creation of
any indebtedness represented thereby, against any incorporator, shareholder, officer or director, as such, past, present or future, of the Company or of any successor corporation, either directly or through the Company or any successor corporation,
whether by virtue of any constitution, statute or rule of law or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issue hereof, expressly waived
and released. 

 THIS SECURITY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW
YORK. 
 All terms used in this Security (and not otherwise defined in this Security) that are defined in the Senior Indenture shall have
the meanings assigned to them in the Senior Indenture.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]